The investment report on Geron Corp. (Nasdaq:GERN) should be of particular interest to other biopharmaceutical companies: ThermoGenesis Corp. (Nasdaq:KOOL), StemCells Inc. (Nasdaq:STEM) and Aastrom Biosciences Inc. (Nasdaq:ASTM).

It is available at: http://investorsoup.com/lp/GERN/

Read and post on Twitter and top Stock Message Boards for these stocks and more, all in real-time: http://www.BoardCentral.com/

Geron Corp. (GERN), a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The Company develops a range of anti-cancer therapies, including anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines, and also focuses on the development of products using telomerase as a marker for cancer diagnosis, prognosis, patient monitoring and screening.

In the report, the analyst notes:

"In January, 2009, GERN became the first company to receive FDA approval to conduct early stage clinical trials on its stem-cell based therapy, aimed at treating severe spinal cord injuries. The FDA has granted clearance of the Company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1. The clearance enables GERN to move forward with the world's first study of a human embryonic stem cell (hESC)-based therapy in man.

"GERN has a broad intellectual property portfolio of issued patents and pending patent applications, which supports its product development and out-licensing activities. On the embryonic stem cell side, GERN now owns or licenses 34 issued U.S. patents, 60 issued foreign patents, and more than 230 patent applications pending worldwide covering various aspects of stem cell technology."

To read the entire report visit: http://investorsoup.com/lp/GERN/

InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup, please visit http://www.InvestorSoup.com

InvestorSoup Disclosure

InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.

This news release was distributed by GlobeNewswire, www.globenewswire.com

 CONTACT:  InvestorSoup.com           Jeffrey Brown, Editor           (469)-252-3505           info@investorsoup.com 

A service of YellowBrix, Inc.